NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $168.02 -2.61 (-1.53%) As of 02:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Quest Diagnostics Stock (NYSE:DGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Quest Diagnostics alerts:Sign Up Key Stats Today's Range$166.30▼$173.3050-Day Range$155.32▼$176.8152-Week Range$125.42▼$178.87Volume1.51 million shsAverage Volume919,339 shsMarket Capitalization$18.65 billionP/E Ratio21.86Dividend Yield1.90%Price Target$179.57Consensus RatingModerate Buy Company OverviewQuest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Read More… Remove Ads Quest Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreDGX MarketRank™: Quest Diagnostics scored higher than 95% of companies evaluated by MarketBeat, and ranked 38th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingQuest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageQuest Diagnostics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quest Diagnostics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth8.14% Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 8.14% in the coming year, from $9.70 to $10.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 22.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.46.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 22.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.88.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quest Diagnostics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.50% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 7.39%, indicating that investor sentiment is decreasing significantly. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.77%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 41.61%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 30.51% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. Sustainability and ESG4.7 / 5Environmental Score-0.62 Percentage of Shares Shorted2.50% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 7.39%, indicating that investor sentiment is decreasing significantly. News and Social Media4.0 / 5News Sentiment1.16 News SentimentQuest Diagnostics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Quest Diagnostics this week, compared to 13 articles on an average week.Search Interest10 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows13 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,423,755.00 in company stock.Percentage Held by InsidersOnly 0.79% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address DGX Stock News HeadlinesQuest Diagnostics Incorporated (NYSE:DGX) SVP Michael E. Prevoznik Sells 4,643 SharesMarch 20, 2025 | insidertrades.comQuest Diagnostics Incorporated (NYSE:DGX) EVP Sells $935,078.10 in StockMarch 8, 2025 | insidertrades.comEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.April 4, 2025 | Colonial Metals (Ad)Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gainsApril 4 at 2:15 AM | marketwatch.comQuest Diagnostics initiated with a Buy at Redburn AtlanticApril 2 at 11:02 PM | markets.businessinsider.comRedburn Atlantic Initiates Coverage of Quest Diagnostics (DGX) with Buy RecommendationApril 2 at 6:01 PM | msn.comQuest Diagnostics Incorporated (NYSE:DGX) Passed Our Checks, And It's About To Pay A US$0.80 DividendApril 2 at 6:01 PM | finance.yahoo.comDigi Power Reports 115% Quarterly Revenue Growth in Q1 2025, Maintains Debt-Free Operations and Strengthens Cash PositionApril 2 at 7:59 AM | markets.businessinsider.comSee More Headlines DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $150.86 on January 1st, 2025. Since then, DGX stock has increased by 13.6% and is now trading at $171.3150. View the best growth stocks for 2025 here. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) released its quarterly earnings data on Thursday, January, 30th. The medical research company reported $2.23 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.04. Quest Diagnostics had a net margin of 8.80% and a trailing twelve-month return on equity of 15.07%. Read the conference call transcript. Does Quest Diagnostics have any subsidiaries? Quest Diagnostics subsidiaries include these companies: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others. When did Quest Diagnostics IPO? Quest Diagnostics (DGX) raised $12 million in an initial public offering on Tuesday, January 7th 2025. The company issued 2,300,000 shares at $4.00-$6.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO. Who are Quest Diagnostics' major shareholders? Quest Diagnostics' top institutional investors include MassMutual Private Wealth & Trust FSB (0.02%), First Financial Bank Trust Division and First Hawaiian Bank. Insiders that own company stock include Stephen H Rusckowski, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Timothy M Ring, Vicky B Gregg, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), General Electric (GE) and ServiceNow (NOW). Company Calendar Record date for 1/29 Dividend1/14/2025Ex-Dividend for 1/29 Dividend1/14/2025Dividend Payable1/29/2025Last Earnings1/30/2025Today4/04/2025Record date for 4/21 Dividend4/07/2025Ex-Dividend for 4/21 Dividend4/07/2025Dividend Payable4/21/2025Next Earnings (Estimated)4/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryHealth Care Services Current SymbolNYSE:DGX CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees49,000Year Founded1967Price Target and Rating Average Stock Price Target$179.57 High Stock Price Target$195.00 Low Stock Price Target$165.00 Potential Upside/Downside+7.0%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$7.69 Trailing P/E Ratio21.82 Forward P/E Ratio17.29 P/E Growth2.16Net Income$871 million Net Margins8.80% Pretax Margin11.90% Return on Equity15.07% Return on Assets6.72% Debt Debt-to-Equity Ratio0.82 Current Ratio1.10 Quick Ratio1.02 Sales & Book Value Annual Sales$9.87 billion Price / Sales1.89 Cash Flow$13.09 per share Price / Cash Flow12.82 Book Value$61.04 per share Price / Book2.75Miscellaneous Outstanding Shares110,978,000Free Float110,733,000Market Cap$18.62 billion OptionableOptionable Beta0.78 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NYSE:DGX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.